The United Kingdom and the United States have forged a major bilateral deal that will keep zero import taxes on British drug products being sold in the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has pledged to boost expenditure on drugs through the National Health Service (NHS). This commitment guarantees that duties on these key goods will be held at nothing for a period of three years.
This deal follows earlier warnings to hike tariffs on patented drug imports, with figures discussed reaching double the cost.
"This arrangement between the Britain reinforces the international landscape for new treatments and introduces much-needed balance to American-British pharmaceutical trade," a statement noted.
Economic Importance
Drugs constitute one of the the United Kingdom's most significant export categories to the US, which is easily the biggest market for major UK drugmakers.
Export figures reveal that in the one-year period prior to last September, the UK sold medicines totaling billions to the US. This value made up nearly one-fifth of British export trade in that timeframe.
"This guarantee secures work, stimulates investment and facilitates the UK to emerge as a international leader for medical research," a government official remarked.
Detailed British Pledges
The deal entails several notable pledges from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new medicines to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to raise total health service expenditure on treatments from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. Last year, rebates topped 20%.
Recent Tensions
This agreement comes amid a long-running row between the sector and the British authorities over spending levels and approval rates.
This friction were exacerbated by claims that American patients were paying several times more for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been delayed or scrapped, while major expansions have been pledged toward American operations.
A senior figure acknowledged that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a percentage of its total funding over the previous ten-year period.
